Advice
following a full submission:
baricitinib (Olumiant®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of severe alopecia areata in adult patients.
In two randomised, double-blind, phase III studies in patients with severe alopecia areata, baricitinib was associated with statistically significant improvements in scalp hair regrowth versus placebo.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice894KB (PDF)
Medicine details
- Medicine name:
- baricitinib (Olumiant)
- SMC ID:
- SMC2572
- Indication:
Treatment of severe alopecia areata in adult patients.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 August 2023